• 1. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528
• 2. An approach towards the synthesis of novel fused nitrogen tricyclic heterocyclic scaffolds via GBB reaction?
  Sandip Gangadhar Balwe,Yeon Tae Jeong Org. Biomol. Chem., 2018,16, 1287-1296
• 3. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
• 4. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 5. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoindoles and derivatives Isoindolones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoindoles and derivatives Isoindolines Isoindolones

Comprehensive Guide to Benzenepropanoic acid, α-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]-,(αR)- (CAS No. 310404-47-8)

Benzenepropanoic acid, α-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]-,(αR)- (CAS No. 310404-47-8) is a specialized chiral compound with significant applications in pharmaceutical research and fine chemical synthesis. This enantiomerically pure derivative of benzenepropanoic acid features a unique phthalimide-protected hydroxyl group, making it particularly valuable for asymmetric synthesis and drug development. The compound's (αR)-configuration offers distinct stereochemical properties that are increasingly sought after in modern medicinal chemistry.

The molecular structure of Benzenepropanoic acid, α-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]-,(αR)- combines aromatic character with functional group diversity, featuring both a carboxylic acid moiety and a phthalimido ether linkage. This combination creates interesting reactivity patterns that organic chemists can exploit for various synthetic transformations. Recent literature highlights its growing importance as a building block for chiral drug intermediates, particularly in the development of central nervous system (CNS) active compounds and anti-inflammatory agents.

From a synthetic chemistry perspective, the phthalimide protecting group in CAS 310404-47-8 offers several advantages. It provides excellent stability under various reaction conditions while being readily removable when needed. This characteristic makes the compound particularly useful in multi-step organic synthesis, where protecting group strategies are crucial. Researchers have successfully employed this compound in the synthesis of optically active β-amino acids and chiral auxiliaries for asymmetric catalysis.

The pharmaceutical industry has shown increasing interest in Benzenepropanoic acid, α-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]-,(αR)- due to its potential applications in drug discovery programs. Its structural features make it a valuable scaffold for developing enzyme inhibitors and receptor modulators. Recent patent literature reveals its incorporation into novel compounds targeting neurodegenerative diseases and chronic pain management, aligning with current healthcare priorities in aging populations.

Analytical characterization of CAS 310404-47-8 typically involves advanced techniques such as chiral HPLC, NMR spectroscopy, and mass spectrometry to confirm its enantiomeric purity and structural integrity. The compound generally appears as a white to off-white crystalline powder with specific optical rotation values that serve as important quality control parameters. Storage recommendations usually suggest protection from moisture and maintenance at controlled room temperature to preserve its chemical stability.

In the context of green chemistry initiatives, researchers are exploring more sustainable synthetic routes to Benzenepropanoic acid, α-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]-,(αR)-. Recent advancements include catalytic asymmetric methods and biocatalytic approaches that reduce the environmental impact of its production. These developments respond to growing industry demands for eco-friendly chiral synthesis and align with global sustainability trends in chemical manufacturing.

The market for chiral building blocks like CAS 310404-47-8 has seen steady growth, driven by expanding pharmaceutical pipelines and increased focus on single-enantiomer drugs. Industry reports indicate particular demand from contract research organizations and academic institutions engaged in medicinal chemistry projects. The compound's commercial availability from specialized suppliers has improved in recent years, though it remains a low-volume, high-value chemical primarily used in research settings.

From a regulatory perspective, Benzenepropanoic acid, α-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]-,(αR)- is not currently classified under major chemical control regulations, though proper laboratory safety protocols should always be followed when handling any chemical substance. Material Safety Data Sheets (MSDS) provide detailed handling instructions, emphasizing standard precautions for organic compound manipulation in research environments.

Future research directions for CAS 310404-47-8 may explore its potential in bioconjugation chemistry and prodrug design, leveraging its functional group compatibility with biological systems. The compound's versatility positions it well for emerging applications in targeted drug delivery systems and therapeutic antibody conjugation, areas experiencing rapid growth in biopharmaceutical development.

For researchers considering Benzenepropanoic acid, α-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]-,(αR)- in their work, it's advisable to consult recent literature on its synthetic applications and consider its stereochemical implications in molecular design. The compound's unique combination of aromatic character, chiral center, and protecting group chemistry offers numerous possibilities for innovative chemical solutions in pharmaceutical and materials science applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)